On average, the facilities with Hb ≥ 10 g/dL, as the target for lower levels of Hb during anemia treatment, produced hb levels of 10.7, 11, and 11.5 g/dL in the US, Brazil, and Germany, respectively. The gene discussed is GSTM1; the disease is anemia.